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Abstract
Estrogen deficiency leads to an upregulation of TNF-a producing T cells and B-lymphopoesis which augments
osteoclastogenesis. Estrogen deficiency also increases the population of premature senescent CD4
+CD28null T cells which
secrete a higher amount of TNF-a thus leading to enhanced osteoclastogenesis. Isoflavonoids like daidzein and genistein
are found mostly in soybeans, legumes, and peas. These share structural similarity with 17b-stradiol (E2) and have
osteoprotective role. This study explores the effect of daidzein (Daid) on the proliferation of TNF-a producing T cells,
premature senescent T cells and B cell lymphopoesis under estrogen deficient conditions. For this study adult Balb/c mice
were treated with Daid at 10 mg/kg body weight dose by oral gavage daily post ovariectomy (Ovx). After six weeks animals
were autopsied and bone marrow and spleen cells were collected for FACS analysis. Blood serum was collected for ELISA. It
was observed that Ovx mice treated with Daid for six weeks show reduction in Ovx induced expansion of CD4
+ T cells in
bone marrow and spleen when analysed by flow cytometry. Estrogen deficiency led to increased prevalence of TNF-a
secreting CD4
+CD28null T cells, however, treatment with Daid increased the percentage of CD4
+CD28
+ T cells. Co-culture of
CD4
+CD28null T cells and bone marrow resulted in enhanced osteoclastogenesis as evident by increased tartarate resistant
acid phosphatase (TRAP) expression, an osteoclast marker. However, treatment with Daid resulted in reduced
osteoclastogenesis in CD4
+CD28null T cells and bone marrow cell co-culture. Daid also regulated B lymphopoesis and
decreased mRNA levels of RANKL in B220
+ cells. Taken together, we propose that one of the mechanisms by which Daid
prevents bone loss is by reversing the detrimental immune changes as a result of estrogen deficiency.
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Introduction
It is now well recognized that one of the mechanism by which
estrogen deficiency leads to increased bone loss is by stimulating
osteoclast formation. Studies by Roggia et al. [1] have shown that
in the bone wasting induced by estrogen deficiency, activated T
cells play an essential causal role. Ovariectomy (Ovx) up regulates
the production of TNF (Tumor necrosis factor)-a secreting T cells.
The amount of TNF-a produced by T cells of Ovx mice is suf-
ficient to augment receptor activator of nuclear factor kappa-B
ligand (RANKL)-induced osteoclastogenesis [1]. Immunopheno-
typical analyses of peripheral blood lymphocyte reveal that several
subsets of T lymphocytes (CD3
+, CD4
+ and CD8
+) are increased
in osteoporotic patients [2,3,4].
Additionally, there is a steady decline in bio available estrogen
in aging men and women, superimposed with decrease in estrogen
level in women at menopause. Thus, E2 deficiency signals the
onset of senescence. The most evident phenotypic change in cellular
senescence is the loss of CD28 [5,6], a T cell-restricted membrane
glycoprotein that provides requisite co-stimulatory signal for the
generation of T cell-mediated immune responses [5,7]. CD28null T
cells are thought to be biological indicators of immunosenescence
[5].AlthoughCD28isconstitutivelyexpressedonallTcells,CD28null
T cells are typically found in the aging immune system, in both
CD4
+ and CD8
+ subsets [5,7,8,9,10]. Also, there is increasing evi-
dence that CD28 null T cells area commonfeature ofinflammatory
conditions like rheumatoid arthritis [5]. Studies in our lab have
shown that there is increased prevalenceof CD28null T cells in Ovx
mice which secrete high amount of TNF-a [11]. Apart from T cells,
Ovx selectively stimulates B-lymphopoiesis which results in marked
accumulation of B220
+ B cells in mouse bone marrow [12]. In vitro
studies have demonstrated that mature B cells have the potential to
both positively and negatively impact osteoclastogenesis by virtue of
their capacity to secrete pro-osteoclastogenic cytokines including
RANKL, as well as anti-osteoclastogenic cytokines such as os-
teoprotegerin (OPG) and TGF-b [13].
Although E2 supplementation protects against Ovx-induced
bone loss, E2 replacement therapy (ERT) is less popular in post-
menopausal women because of increased risk of breast and uterine
cancers in women taking ERT [14]. A growing body of literature
suggest that phytoestrogens may confer substantial benefits to bone
health without posing the risk of cancer associated with E2
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most common form of phytoestrogens. These share structural
similarity to the estrogen 17ß- estradiol and have been shown to
have bone protective effect in vitro and in vivo [17]. High dietary
intake of these isoflavones have been reported to increase BMD in
lumbar spine of Japanese [18], Chinese [19] and American [20]
postmenopausal women. At micromolar concentrations in vitro,
genistein and daidzein promote osteoblast functions via estrogen
receptor (ER)-dependent mechanism [21]. Oral or subcutaneous
injections of genistein and daidzein inhibit bone loss in ovari-
ectomized or orchidectomized mice [22].
Amongst the two isoflavones, genistein has been most widely
studied for its effect on immunity. It inhibits the lymphocyte
proliferation induced by mitogen and alloantigen in vitro [23].
Genistein induces dose-responsive reductions in thymus weight in
Ovx mice [24]. Like estrogen, genistein prevented the elevation of
B-lymphopoiesis in the bone marrow of Ovx mice [25]. Immune
effects of genistein have shown to be both ER dependent and ER
independent [23]. However, data on Daid mediated immune effects
is very limited. In this study we attempt to provide a possible role of
dietaryisoflavonoid,Daidinimmunity. In an earlier study we found
that E2 as well as Medicarpin reduce the Ovx induced proliferation
of TNF-a secreting T cells and decrease the prevalence of pre-
mature senescent cells producing high amounts of TNF-a post Ovx
[11]. Here, we evaluate the immunomodulating effect of Daid at its
osteoprotective dose on TNF-a producing T cell proliferation and
further, if it inhibits the Ovx induced increase in TNF-a secreting
CD4
+CD28null T cells. We have also determined if these prema-
ture senescent cells secreting higher amounts of TNF-a contribute
to enhanced osteoclastogenesis and if Daid inhibits this phenom-
enon. Additionally, we also study the effect of Daid on B-lym-
phopoesis post Ovx and the cytokines (OPG and RANKL) secreted
by B cells.
Results
Effect of Daid on Ovx induced gain in thymus and spleen
weight at its osteoprotective dose
Mice Ovx for 6 weeks exhibited deterioration of trabecular
microarchitecture compared with sham, and Ovx mice treated
with Daid (10.0 mg kg
21.day
21) or E2 (0.01 mg.kg
21.day
21) for 6
weeks protected against Ovx-induced loss of trabecular micro-
architecture (Table 1). It is well known that Ovx leads to an
increase in thymic weight and cellularity, and E2 administration
causes thymic atrophy [26]. As expected, there was increase in
thymus weight in Ovx mice (Table 2). In addition, Ovx also
induces gain in spleen weight [27]. However, treatment with Daid
at its osteoprotective dose inhibited the Ovx induced increase in
thymus and spleen weight (Table 2).
Role of Daid on Ovx-induced ROS generation and
enhanced circulating TNF-a level
Ovariectomy causes an accumulation of reactive oxygen species
in the BM, which leads to increased production of TNF-a by
activated T cells through upregulation of the costimulatory
molecule CD80 on dendritic cells [28]. Our data show that Ovx
led to significant increase in ROS production compared to sham
group (Fig. 1A). However, treatment with Daid led to significant
reduction in ROS production (Fig. 1A). E2 deficiency is known to
increase circulating TNF-a levels [1]. Our data show that Ovx
mice had significantly higher circulating levels of TNF-a com-
pared with sham group. Ovx mice treated with Daid had reduced
TNF-a level that were comparable to that of sham group (Fig. 1B).
Further, mice Ovx for 6 weeks had ,2.0-fold higher TNF-a
mRNA levels in BM CD4
+ T cells compared with sham (Fig. 1C).
Daid treatment of Ovx mice significantly reduced TNF-a mRNA
levels compared to Ovx control group (Fig. 1C). E2 was taken as a
positive control.
Role of Daid on Ovx induced expansion of BM and
Spleen CD4
+ cells
Ovx is known to increase proliferation of CD4
+ T cells [1]. Mice
Ovx for 6 weeks have higher frequency of CD4
+ T cells in BM
compared with sham group (Fig. 2A). Treatment of Ovx mice with
either Daid resulted in ,50% reduction in the frequency of CD4
+
T cells in BM compared with Ovx group (Fig. 2A). Effect of Ovx
on the secondary lymphoid organ (spleen) was also studied, and we
found that Daid decrease the Ovx induced expansion of CD4
+
cells in spleen (Fig. 2B). E2 was taken as a positive control.
Effect of Daid on Ovx-induced loss of CD28 expression in
BM and Spleen T cells
CD28 is the surface glycoprotein expressed on CD4
+ and CD8
+
T cells and loss of CD28 expression is an indicator of T cell
senescence [5,7]. Percentage of CD4
+CD28
+ T cells in BM of Ovx
mice was significantly less than sham group (Fig. 3A and B). Ovx
mice treated with Daid had significantly higher frequency of
Table 1. m-CT analysis of femur trabeculae of Balb/C Mice.
Paramete Sham OVX OVX+E2 0.01 mg/kg/day OVX+Daid 10 mg/kg/day
Percent bone volume
(BV/TV)
22.767.66*** 7.3460.302 18.8466.88*** 9.32262.36*
Trabecular separation
Tb.Sp(mm)
0.2460.03*** 0.5260.12 0.3860.11*** 0.3860.09**
Trabecular number
Tb.N(1/mm)
2.8360.75*** 1.1160.07 2.1960.67*** 1.3960.29*
Trabecular pattern factor
Tb.Pf
10.2465.72*** 18.7062.9 11.2064.40*** 15.8062.68*
Micro computed tomographic (mCT) determination of excised femora were carried out using the Sky Scan 1076 KCT scanner (Aartselaar, Belgium).Trabecular bone
volume (BV/TV; %), trabecular separation (TbSp), trabecular number (TbN), and trabecular pattern factor were calculated by the mean intercept length method. N=10
mice/group; data are presented as mean 6 SEM;
*P,0.05,
**P,0.01,
***P,0.001 compared with Ovx+vehicle group.
doi:10.1371/journal.pone.0021216.t001
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+CD28
+ T cells in BM compared with Ovx + vehicle group
(Fig. 3A and B). Pattern of CD28 expression was found to be
similar in Splenic CD4
+ T cells. Daid significantly increased CD28
expression on CD4
+ T cells compared to Ovx + vehicle group
(Fig. 3C). E2 was taken as a positive control.
Effect of Daid in co-culture of bone marrow cells and
TNF-a secreting CD4
+CD28null T cells
It is established that there is an increased proliferation of TNF-a
producing T cells in estrogen deficient ovx mice [1]. In an earlier
study [11], we have shown that this increase in TNF-a is mainly
contributed by CD4
+CD28null T cells where TNF-a mRNA
levels were several folds higher in CD4
+CD28null T cells com-
pared to CD4
+CD28
+ T cells isolated from BM. Increased TNF-a
production may lead to enhanced osteoclastogenesis directly or by
augmenting RANKL production [1]. Thus it was interesting to
study if co-culture of CD4
+CD28null T cells with osteoclast pre-
cursor cells may lead to enhanced osteoclastogenesis. We observed
that transcript levels of TRAP were significantly higher in BM cells
co-cultured with CD4
+CD28null T cells. Treatment with Daid
and E2 led to a significant decrease in the transcript levels of
TRAP in CD4
+CD28null cells co-cultured with BM cells (Fig. 4A).
Conditioned media was collected for determining TNF-a level. It
was observed that while TNF-a levels were higher in conditioned
media of BM cells co-cultured with CD4
+CD28null T cells,
treatment with Daid and E2 decreased these levels and brought it
back nearly to the basal level (Fig. 4B).
Effect of Daid on transcript levels of nucleolin and
hnRNP-D0A genes vital for CD28 gene expression
Nucleolin and hnRNP-D0A are proteins responsible for CD28
expression on T cells [7,8]. Our data show that CD4
+ T cells in
BM of Ovx mice had significantly lower mRNA levels of CD28,
nucleolin and hnRNP-D0A compared with sham group (Fig. 5A,
B and C). Daid treatment of Ovx mice also led to a significant
increase in mRNA levels of all the three genes i.e. CD28, nucleolin
and hnRNP-D0A in CD4
+ T cells, however less than that of
Ovx+E2 treated group (Fig. 5A, B and C).
Table 2. Thymus and spleen weight in Balb/c mice.
Parameter Sham Ovx
Ovx+E2
0.01 mg/kg/day OVX+Daid 10 mg/kg/day
Thymus
Wt (mg)
48.3663.11*** 67.2763.45 47.5463.52*** 44.8763.14***
Spleen
Wt (mg)
83.1063.13*** 100.263.15 82.1062.69*** 82.3763.88***
Daid treatment decreases Ovx-induced increase in thymus and spleen weight. N=10 mice/group). Data are presented as mean 6 SEM;
***P,0.001 compared with Ovx+vehicle group.
doi:10.1371/journal.pone.0021216.t002
Figure 1. Daid treatment inhibits Ovx-induced oxidative stress in CD4
+ T cells and TNF-a production by these cells. (A) Cellular ROS
measurement was performed by incubating CD4
+ T cells with DCF-DA followed by FACS analysis. (B) Circulating TNF-a levels were measured in
various groups by ELISA. (C) TNF-a mRNA levels in the BM CD4
+ T cells were measured in various groups by qPCR. N=10 mice/group; data are
presented as mean 6 SEM;
**P,0.01 and
***P,0.001 compared with Ovx+vehicle group.
doi:10.1371/journal.pone.0021216.g001
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CD28 on CD4
+ BM cells in vitro
We next studied the effect of Daid on TNF-a induced sup-
fopression of CD28 levels in BM CD4
+ cells and whether Daid
mediated this effect via ERs. Purified CD4
+ T cells were exposed
to various treatments as shown in (Fig. 6) and CD28
+ T cells were
quantified by flow cytometry. Exogenous TNF-a significantly
reduced the frequency of CD28
+ T cells, while Daid attenuates
TNF-a induced reduction of CD28
+ T cells (Fig. 6). Presence of an
anti-estrogen, ICI-182,780, blunted the ability of Daid to
attenuate TNF-a induced reduction of CD28
+ T cells.
Role of Daid in Ovx induced elevation of B-lymphopoesis
Ovx is known to increase the proliferation of B220
+ cells in bone
marrow while estrogen treatment restores the increased level of B-
lymphopoiesis in Ovx mice to the sham level [25]. It was seen that
Figure 2. Daid treatment significantly decreased Ovx-induced increases in CD4
+ T cell subsets in the BM and spleen. (A) CD4
+ T cells
in BM and (B) CD4
+ T cells in spleen were quantified by flow cytometry as described in Materials and Methods. N=10 mice/group; data are presented
as mean 6 SEM;
***P,0.001 compared with Ovx+vehicle group.
doi:10.1371/journal.pone.0021216.g002
Figure 3. Daid treatment prevented Ovx-induced loss of CD28 on the BM as well as in spleen CD4+ T cells. (A) Representative image (B)
CD4
+CD28
+ T cells in BM, (C) Representative image (D) CD4
+CD28
+ T cells in spleen of Sham, Ovx, Daid and E2 were measured by flow cytometry as
described in Materials and Methods. N=10 mice/group; data are presented as mean 6 SEM;
***P,0.001 compared with Ovx+vehicle group.
doi:10.1371/journal.pone.0021216.g003
Daidzein Inhibits Premature T Cell Senescense
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21216Figure 4. Daidzein inhibits increased osteoclastogenesis in co-culture of bone marrow cells and TNF-a secreting CD4
+CD28null T
cells. (A) TRAP mRNA expression by qPCR in co-culture of BM cells and CD4
+CD28null T cells. N=3 mice/group; data are presented as mean 6 SEM;
***P,0.001 compared with untreated co-culture of CD4
+CD28null T cells with BM cells. (B) TNF-a levels were measured in the co-culture by ELISA.
N=3 mice/group; data are presented as mean 6 SEM;
***P,0.001 compared with untreated co-culture of CD4
+CD28null T cells with BM cells.
doi:10.1371/journal.pone.0021216.g004
Figure 5. Daid treatment increased CD28, nucleolin and hnRNP-D0A mRNA levels assessed by qPCR in the BM T cells of Ovx mice.
mRNA levels of CD28, nucleolin and hnRNP-D0A in CD4
+ T cells (A–C). All data are the mean 6 SD of three independent experiments; n=3 mice/
group;
*P,0.05,
**P,0.01,
***P,0.001 compared with Ovx+vehicle group.
doi:10.1371/journal.pone.0021216.g005
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+ cells in BM
compared with sham group (Fig. 7A and B). Treatment of Ovx
mice with Daid resulted in more than 50% reduction in the
frequency of B220
+ cells in BM compared with Ovx group (Fig. 7A
and B). E2 was taken as a positive control.
Additionally, estrogen deficiency upregulates the production of
RANKL from B cells [29] which is an important factor for
osteoclastogenesis. B cells are also a source of osteoprotegrin,
decoy receptor for RANKL [30]. It was seen that in B220
+ cells
isolated from Ovx mice, the transcript levels of OPG were very
low compared to those isolated from sham group (Fig. 7C).
Treatment of Ovx mice with Daid led to an increase in OPG levels
however, E2 effect was more robust (Fig. 7C). Mice Ovx for 6
weeks show increased transcript levels of RANKL compared to
sham group in B220
+ cells (Fig. 7D). Treatment of Ovx mice with
Daid led to a decrease in RANKL transcript levels (Fig. 7D).
Discussion
Daid (10.0 mg.kg
21.day
21 dose) or E2 (0.01 mg.kg
21.day
21
dose) given for 6 weeks to Ovx mice protected against Ovx-
induced loss of trabecular microarchitecture (Table 1). At this
Figure 6. Daid abrogates TNF-a mediated CD28 downregulation in the BM CD4
+ T cells. (A) BM CD4
+ T cells (5610
5 cells/well) were
seeded in 24-well plates. For ICI 182,780 (ICI) treatment group, the cells were pre-treated with ICI for 30 min. Various treatments as shown were given
to CD4
+ T cells for 24 h [E2-10
29 M, Daid 210
28 M, TNF-a210.0 ng/ml]. At the end of incubation, cells were stained with antibodies against CD3,
CD4 and CD28 and subjected to flow cytometry as described in Materials and Methods. Data are presented as mean 6 SEM from 3 independent
experiments;
***P,0.001 compared with TNF-a treated cells and
cP,0.001 compared between Daid+TNF-a and Daid+TNF-a+ICI treated cells; E2+TNF-
a and E2+TNF-a+ICI treated cells.
doi:10.1371/journal.pone.0021216.g006
Figure 7. Daid treatment significantly decreased Ovx-induced increases in B220
+ cells in BM. (A and B) B220
+ cells in BM were quantified
by flow cytometry as described in Materials and Methods. (C) OPG mRNA levels in the BM B220
+ cells were measured in various groups by qPCR. (D)
RANKL mRNA levels in the BM B220
+ cells were measured in various groups by qPCR. N=10 mice/group; data are presented as mean 6 SEM;
*P,0.05,
**P,0.01,
***P,0.001 compared with Ovx+vehicle group.
doi:10.1371/journal.pone.0021216.g007
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several Ovx-induced changes including 1) increased thymic and
spleen weight, 2) increased TNF-a expression in BM CD4
+ T cells,
3) increased circulating TNF-a levels, 4) increased population of
BM and Spleen CD4
+ T cells, 5) reduced CD28 expression on BM
and Spleen CD4
+ T cells, 6) increased B-lymphopoesis in BM cells.
Ovx is known to increase the thymic and spleen weight which
contributes to increased thymic T cell output and B cell ma-
turation leading to more bone loss [26,31]. Genistein has been
shown to cause thymus involution in mice [32,33]. Previous
reports have shown that while E2 treatment led to 50% decrease
in thymus weight, genistein at a dose of 80 mg/kg and 200 mg/kg
body weight dose led to a drastic decrease (73% and 78% decrease
respectively) in thymus weight suggesting the possibility of thymic
abnormalities [32]. In our case Ovx mice were treated with
10 mg/kg body weight dose of Daid which led to 40% reduction
in thymus weight, almost similar to E2 treated Ovx mice and thus
appears to be safe (Table 2). Daid also reduced Ovx induced gain
in spleen weight (Table 2).
Reports have suggested that stimulation of TNF-a production
by osteoclasts or BM cells is the mechanism by which ROS cause
bone loss [34]. Studies by Grassi et al. [28] have shown that key
effects of Ovx, the up-regulation of Ag-dependent activation of T
cells and the resulting T cell production of TNF-a, are mediated
by ROS and abolished by treatment with antioxidants. Our data
show that while Ovx led to significant increase in ROS production
by CD4
+ T cells, treatment with Daid inhibited Ovx induced ROS
generation (Fig. 1A). We further observed that the circulating
levels of TNF-a were ,60% higher in Ovx mice compared with
sham, which is in agreement with previous reports [35], and Daid
treatment of Ovx mice totally obliterated Ovx-induced increase in
circulating TNF-a levels (Fig. 1B). Also, TNF-a mRNA levels were
elevated by .2.0-fold in BM CD4
+ T cells of Ovx mice compared
with sham, and Daid treatment completely abolished Ovx-induced
upregulation of TNF-a mRNA levels (Fig. 1C). Together, our data
suggest that Daid alleviates systemic and local (via BM T cells) rises
in TNF-a caused by E2 deficiency and thus prevent bone wasting.
Similar to that in the thymus, Ovx causes an expansion of the T
cell pool in BM (Fig. 2A) and spleen (Fig. 2B) by increasing T cell
proliferation and lifespan [1,36]. We observed that Daid reduced
the proportion of Ovx-induced increases in BM (Fig. 2A) and
spleen CD4
+ T cells (Fig. 2B). Additionally, Daid completely
mitigated Ovx-induced loss of CD28 on CD4
+ T cells of the BM
and spleen. According to inflammation theory of aging, T cells
deficient in CD28 expression become prematurely senescent and
acquire the ability to produce pro-inflammatory cytokines. In
mammals, E2 deficiency is an aging process, signalling the end of
reproductive life [37]. We observed that Ovx resulted in loss of
CD28 expression in BM and spleen T cells (Fig. 3). Supplementing
Ovx mice with Daid restored the percentage of CD28
+ T cells in
both BM and spleen cells (Fig. 3). These data suggest that Ovx
triggers T cell senescence in the BM as well as in spleen by
reducing CD28 expression and Daid counteracts this loss.
Our earlier study [11] has shown that increased mRNA levels of
TNF-a is mainly contributed by CD4
+CD28null T cells. As TNF-
a directly or by augmenting RANKL secretion may lead to
enhanced osteoclastogenesis it was studied if CD4
+CD28null T
cells co-cultured with osteoclast precursor cells lead to increased
osteoclast differentiation. We found that TRAP mRNA expression
was significantly more in CD4
+CD28null T cells co-cultured with
BM cells compared to control and treatment with Daid and E2
decreased TRAP transcript levels in the co-culture (Fig. 4B).
Moreover, TNF-a levels when determined by ELISA in con-
ditioned media of CD4
+CD28null T cells co-cultured with BM
cells were higher and were decreased after Daid and E2 treatment
(Fig. 4C).
Next, we determined the mode by which Daid inhibits CD28
loss as a result of ovariectomy. Basal transcription of CD28 gene is
regulated by nucleolin-hnRNP-D0A-site a complex formation in
the CD28 promoter [7,8]. Daid treatment of Ovx mice caused
significantly greater increase in the levels of CD28 mRNA with E2
showing a more robust effect. Also, while nucleolin and hnRNP-
D0 mRNA levels were significantly reduced in CD4
+ T cells in
Ovx mice compared with sham group, treatment of Ovx mice
with Daid significantly enhanced the transcript levels of nucleolin
and hnRNP-D0 mRNA levels in BM CD4
+ T cells (Fig. 5). These
data suggest that Daid prevent loss of CD28 expression by inhi-
biting the reduction in the mRNA levels of nucleolin and hnRNP-
D0A in CD4
+ T cells as a result of ovx.
There is evidence that TNF-a down regulates CD28 expression
onT cellsleadingtotheemergenceofsenescent cellpopulation[38].
We show that treatment of exogenous TNF-a to BM CD4
+ Tc e l l s
resulted in reduced percentage of CD28
+ T cells compared with
vehicle treated CD4
+ T cells, and the presence of Daid with TNF-a
significantly reversed TNF-a-induced loss of CD28. Further, pre-
sence of ICI-182,780 blocked the ability of Daid to reverse TNF-a
induced loss of CD28 on T cells (Fig. 6). Thus, we hypothesize that
Daidmight be actingvia the ERs to abrogate TNF-a-induced loss of
CD28 expression in T cells. This would result in decreased pro-
duction of senescent T cell population that in turn may be responsi-
ble for increased TNF-a production under E2 deficiency.
It has been reported that estrogen deficiency caused by Ovx
selectively stimulates B-lymphopoiesis, resulting in an accumula-
tion of pre-B cells in mouse bone marrow [39]. It was assumed
that the increased B-lymphopoiesis caused by estrogen deficiency
was involved in stimulating bone resorption [12]. Studies on the
isoflavone genistein have shown that it reduces B-lymphopoesis
[25]. Thus, it was studied if Daid also reduces B-lymphopoesis as is
the case with genistein. Our data show that while Ovx led to
significant increase in percent of B220
+ cells in BM compared to
sham, treatment with Daid inhibited this proliferation of B220
+
and brought it back to nearly the sham level (Fig. 7A and B).
Mature B cells have the potential to both positively and negatively
impact osteoclastogenesis by secreting pro-osteoclastogenic cyto-
kines like RANKL, as well as anti-osteoclastogenic cytokines such
as OPG [13]. RANKL/RANK/OPG represents the triad in the
cross-talk between osteoblasts and osteoclasts that regulates osteo-
clastogenesis [40]. Thus, the effect of Daid on OPG and RANKL
mRNA transcripts in B cells was observed. B cells isolated from
Ovx mice and treated with Daid exhibited increased OPG mRNA
level (Fig. 7C) and decreased RANKL mRNA levels (Fig. 7D)
compared with Ovx control mice, with E2 showing much robust
effect.
To conclude, our results reveal that Daid reverses detrimental
immunological changes resulting from E2 deficiency provides
protection against bone loss. Based on our findings, we propose
that Daid prevents bone loss by (i) inhibiting the proliferation of
TNF-a producing CD4
+CD28null T cells, (ii) preventing prema-
ture T cell senescence via increasing mRNA levels of nucleolin,
hnRNP-D0A, and CD28 in BM T and by antagonizing TNF-a-
induced loss of CD28 expression via ER and (iii) by inhibiting Ovx
induced B-lymphopoesis.
Material and Methods
Reagents and chemicals
Mouse lymphocytes from bone marrow and spleen were
cultured in complete RPMI-1640 medium (Wisent Inc., St-Bruno,
Daidzein Inhibits Premature T Cell Senescense
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Penicillin (500 U/ml), Streptomycin (500 mg/ml). Trizol was
purchased from GIBCO-BRL, Invitrogen corp., Carlsbad, CA;
TNF-a and DCF-DA from Sigma-Aldrich (St. Louis, MO, USA).
RPE-cy-7, PE-cy-5.5-conjugated anti-mouse CD4, FITC conju-
gated anti-mouse CD28 and APC conjugated anti-mouse B220
+
antibodies were purchased from BD Biosciences (Mississauga, ON,
CA). CD4 (L3T4), CD28, and B220
+ microbeads were purchased
from Miltenyi Biotech, Germany and TNF-a ELISA kit from
Immunodiagnostic systems Ltd. UK.
In vivo study
The study was conducted in accordance with current legislation
on animal experiments (Institutional Animal Ethical Committee
at Central Drug Research Institute) and was approved by the
Institutional animal ethics committee. Approval ID for this study
was 39/10/ENDO/IAEC dated 22.1.2010. Adult Balb/c mice
(9–10 week-old) were taken for the study [41,42,43,44]. All mice
were housed at 25uC, in 12-hour light:12-hour dark cycles. Nor-
mal chow diet and water were provided ad libitum. Ten mice per
group were taken for the study, and all rats in each group were
assayed and included in the statistical analyses (n=10). The
groups were as follows: sham-operated (ovary intact) mice, which
served as the control group and were given vehicle (gum acacia in
distilled water); Ovx+vehicle; Ovx+0.01 mg.kg
21.day
21 E2 [45,
46]; and Ovx+10 mg.kg
21.day
21 daidzein (Daid) [47]. All
treatments were given by oral gavage and continued for 6 weeks.
At the completion of study, animals were autopsied. After autopsy,
bones were dissected and the bone marrow (BM) was flushed out.
Total lymphocytes from the BM were isolated by using Hisep
LSM 1084 (Himedia) by means of density (1.08460.0010 g/ml)
gradient centrifugation technique [48,49]. Pure CD4
+,C D 4
+CD28
+
and CD4
+CD28null T and B220
+ cells were retrieved from the BM
by positive and negative selection using microbeads based isolation
by MACS separator according to the manufacturer’s protocol
(EasySep Biotin Selection Kit, Stem Cell Technologies Inc., Van-
couver, BC, CA). These purified cells were then collected in Trizol
for Real time PCR (qPCR). Thymuses and spleens were collected
and weight recorded. Serum was collected for ELISA. Serum TNF-
a was measured in all the groups by using ELISA kit according to
manufacturer’s instructions.
Flow cytometry
Cells from the BM/Spleen were labelled with anti CD3, CD4 ,
CD28 and B220 antibodies (APC conjugated anti-mouse CD4,
PE-cy-5.5-conjugated anti-mouse CD4, FITC conjugated anti-
mouse CD28 and APC conjugated anti B220 antibodies) to assess
the percentage of CD4
+, CD4
+CD28
+ in CD3
+ cells and B220
+
(CD45RO) cells. Specificity of immunostaining was ascertained by
the background fluorescence of cells incubated with Ig isotype
controls. Fluorescence data from at least 10,000 cells were col-
lected from each sample. Immunostaining was done as per
manufacturer’s instructions. In brief, single cell suspension of the
BM was prepared in PBS. Then cells were centrifuged at 500 rpm
for 5 minutes. Supernatant was discarded and cells were sus-
pended in 1 ml of PBS. Cells were counted using haemocytometer
and were resuspended in PBS as 10
6 cells/100 ml PBS and anti-
body were added as 10 ml/10
6 cells and further incubated for
45 minutes at room temperature. After incubation cells were
washed twice with PBS and transferred to FACS tubes for analysis.
FACS Caliber and FACS Arya (BD Biosciences Mississauga, ON,
CA) were used to quantify the percentage of CD4
+, CD4
+CD28
+
T cells in CD3
+ cells and B220
+ B cells in all the groups [50].
Bone Marrow- CD4
+CD28null T cell Co-culture
For bone marrow-T cell co-culture, bone marrow cells (BMCs)
were isolated from 4- to 6 week old mice by flushing bone marrow
from the excised femora with osteoclast cell culture medium
containing 10% FCS. Cells were cultured overnight in osteoclast
culture medium containing macrophage-colony stimulating factor
(MCSF) (7 ng/ml). After overnight incubation, non-adherent
bone marrow cells were added to purified CD4
+CD28null T cells
in osteoclast culture medium containing M-CSF (30 ng/ml) and
receptor activator of nuclear factor kappa-B ligand (RANKL)
(50 ng/ml). After six days in culture, cells were harvested for RNA
and cDNA synthesis. Transcript level of tartarate resistant acid
phosphatase (TRAP), an osteoclastogenic marker, was deter-
mined by q-PCR. Conditioned media was collected for TNF-a
ELISA.
Total RNA isolation and quantitative Real-Time-PCR
Total RNA was extracted from isolated CD4
+, CD4
+CD28
+
and CD4
+CD28null T and B220
+ cells of all the in vivo groups and
in vitro cultured cells using Trizol (Invitrogen). cDNA was syn-
thesized from 1 mg total RNA with the Revert AidTM H Minus
first strand cDNA synthesis kit (Fermentas, USA). SYBR green
chemistry was used for quantitative determination of the mRNAs
for CD28, Nucleolin, hn-RNP-D0A, OPG, RANKL, TRAP, TNF-
a and a housekeeping gene, GAPDH, following an optimized
protocol. The design of sense and antisense oligonucleotide primers
was based on published cDNA sequences using the Universal probe
library (Roche Diagnostics, USA). Primer sequences are given in
Table 3. For real-time PCR, the cDNA was amplified with Light
Cycler 480 (Roche Diagnostics Pvt. Ltd.).
The double-stranded DNA-specific dye SYBR Green I was
incorporated into the PCR buffer provided in the Light Cycler 480
SYBER green I master (Roche Diagnostics Pvt. Ltd.) to allow for
quantitative detection of the PCR product in a 20 ml reaction
volume. The temperature profile of the reaction was 95uC for
5 min, 40 cycles of denaturation at 94uC for 2 min, and annealing
and extension at 62uC for 30 sec, extension at 72uC for 30 sec.
GAPDH was used to normalize differences in RNA isolation,
RNA degradation, and the efficiencies of the reverse transcription.
Table 3. Sequences of real-time PCR primers.
Gene Name Primer Sequence Accession Number
CD 28 P1-59-CTGGCCCTCATCAGAACAAT-39
P2-59-GGCGACTGCTTTACCAAAATC-39
NM_007642.4
Nucleolin P1-59-CATGGTGAAGCTCGCAAAG-39
P2-59-TCACTATCCTCTTCCACCTCCTT-39
NM_010880.3
hn-RNO-D0A P1-59-CAAGATCGACGCCAGTAAGA-39
P2-59-GTGTCGTGGGGAGGAGTTT-39
NM_001077266.1
OPG P1-59-GTTTCCCGAAGGACCACAAT-39
P2-59-CCATTCAATGATGTCCAGGAG-39
U94331.1
RANKL P1-59- TGAAGACACACTACCTGACTCCTG-39
P1-59- CCACAATGTGTTGCAGTTCC-39
AF019048.1
TNF-a P1-59-TCTTCTCATTCCTGCTTGTGG-39
P2-59-GGTCTGGGCCATAGAACTGA-39
NM_013693.2
TRAP P1-59-GGTCAGCAGCTCCCTAGAAG-39
P2-59-GGAGTGGGAGCCATATGATTT-39
NM_001102405.1
GAPDH P1-59- AGCTTGTCATCAACGGGAAG -39
P2-59- TTTGATGTTAGTGGGGTCTCG -39
NM_008084.2
doi:10.1371/journal.pone.0021216.t003
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+ cells for TNF-a induced CD28 loss
For this experiment, lymphocytes were isolated by using Hisep
LSM 1084 (Himedia) according to manufacturer’s instructions.
Pure CD4
+ cells were isolated via MACS by using CD4
+ magnetic
beads according to standard protocol. After isolation cells were
seeded overnight in 48 well plates at 5610
5cells/well in 10%
RPMI 1640 media. Cells were incubated Daid (10
28 M) and
10
28 M E2 followed by incubation with TNF-a (10 ng/ml) for
24 h at 37uC. Cells were then incubated with FITC conjugated
anti- CD28, PE-Cy5.5 conjugated anti CD4 and APC conjugated
anti-CD3 antibody for 30 minutes in dark. After incubation cells
were pelleted down and supernatant was discarded. Cells were
washed in PBS. After washing cells were transferred in FACS
tubes and total CD4
+ cells were analysed in CD3
+ cells by FACS
for CD28 expression [51].
For inhibitor studies cells were pre-treated with ICI-182780
(Tocris Bioscience, USA) at 10
29 M concentration thirty minutes
prior to Daid/E2 and TNF-a treatment.
Ex vivo culture of CD4
+ T cells for ROS generation
For ex vivo studies animals were autopsied and total lymphocytes
were isolated from bone marrow of long bone (femur) of animals
by density gradient centrifugation. Pure CD4
+ cells were isolated
by MACS using strandard protocols according to manufacturer’s
instructions. Purified cells were seeded in 48 well plates at a density
of 3610
5cells/well for 24 h in 1% RPMI-1640 medium. For ROS
measurement, cells were incubated with 29 79 -Dichlorofluorescin
diacetate DCF-DA (10 mg/ml concentration) for 30 minutes. After
incubation cells were pelleted and supernatant was discarded.
Cells were washed in PBS. After washing cells were transferred in
FACS tubes and analysed by FACS for ROS generation [51].
Statistical Analysis
Data are expressed as mean 6 S.E.M. The data obtained in
experiments with multiple treatments were subjected to one-way
ANOVA followed by Newman–Keuls test of significance using
Prism version 3.0 software. Student’s t-test was used to study
statistical significance in experiments with only two treatments.
Qualitative observations have been represented following assess-
ments made by three individuals blinded to the experimental
designs.
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